Compare PLAY & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAY | PROK |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 357.3M | 316.0M |
| IPO Year | 2011 | 2021 |
| Metric | PLAY | PROK |
|---|---|---|
| Price | $8.77 | $2.01 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 5 |
| Target Price | ★ $23.83 | $7.40 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 06-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $5.00 | N/A |
| P/E Ratio | $54.50 | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $8.30 | $1.30 |
| 52 Week High | $24.99 | $3.48 |
| Indicator | PLAY | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 39.30 | 70.28 |
| Support Level | N/A | $1.56 |
| Resistance Level | $10.81 | $2.22 |
| Average True Range (ATR) | 0.51 | 0.12 |
| MACD | -0.10 | 0.05 |
| Stochastic Oscillator | 20.11 | 89.44 |
Dave & Buster's Entertainment Inc is an owner and operator of entertainment and dining venues in North America that offer experiences for both adults and families under the Dave & Buster's and Main Event brands. The company combines various forms of entertainment, including games, bowling, and watching live sports and other televised events, with a full menu of entrees and appetizers and a selection of alcoholic and non alcoholic beverages, all in one location. Its concept focuses on providing customers the opportunity to Eat, Drink, Play, and Watch, appealing to a balanced mix of adults, families, and teenagers. The company also operates internationally in the early stage as a franchisor of the Dave & Buster's brand.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.